📈 69% of S&P 500 stocks beating the index - a historic record! Pick the best ones with AI.See top stocks

UBS raises Eisai stock rating to Buy, expects strong growth in Alzheimer's drug

EditorAhmed Abdulazez Abdulkadir
Published 09/09/2024, 18:08
4523
-


On Monday, UBS upgraded shares of Eisai Co (OTC:ESAIY) Ltd (4523:JP) (OTC: ESALY) from Neutral to Buy, with a new price target set at ¥7,500, an increase from the previous ¥6,900. The upgrade follows a reassessment of Eisai's financial projections and the expected growth in sales of its Alzheimer's drug, Leqembi.


The firm raised its earnings per share (EPS) forecasts for Eisai for fiscal years ending March 2025, 2026, and 2027 by 16%, 15%, and 35%, respectively. This optimistic outlook is based on the anticipation that sales of Leqembi will surge in the second half of 2024.


Eisai has reported global sales of Leqembi totaling ¥2.8 billion in the fourth quarter of FY3/24 and ¥6.3 billion in the first quarter of FY3/25. These figures indicate a gradual increase in sales. Although Eisai's target for global Leqembi sales is an ambitious ¥56.5 billion for FY3/25, UBS forecasts sales to reach ¥59 billion, exceeding the company's goal. This projection has been revised upwards from an earlier estimate of ¥30.6 billion.


The firm acknowledges the significant unmet medical needs of Alzheimer's patients and considers Eisai's projection of peak sales of ¥1.3 trillion for Leqembi to be bullish in the current market environment.


However, the treatment's market penetration rate could improve with advancements such as subcutaneous injections and the ability to make definitive diagnoses using blood biomarkers.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.